Our President and Managing Director, Ms. Jennifer Che, and Principal, Ms. Pauli Wong, have been invited by the HKUST, Office of Knowledge Transfer to be speakers at the IP seminar – ‘Bright Ideas, Strong Barriers: A Patenting Masterclass’ on June 26, 2024 (Wednesday) from 15:00-16:15 at the HKUST- Chow Tak Sin Lecture Theater G (LT-G).

The seminar will be divided into two parts and focus on the following topics:

1) IP Basics, Innovation Oversight and Tips: Patent 101 and Top IP Mistakes By Start-Ups & Entrepreneurs by Ms. Pauli Wong

2) MedTech & Healthcare Hurdles: IP Challenges for Innovations in the GBA and China by Ms. Jennifer Che

This seminar is designed to enhance the understanding and awareness on IP and its significance in the academic and research fields.



Our Past Events

Recommended Insights

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

6 December 2021
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]

CNIPA Releases Interim Measures for the Amended Chinese Patent Law Going Into Effect June 1, 2021

28 May 2021
Breaking News! We finally have more details about the new Chinese Patent Law which will go into effect on June 1, 2021. The full set of measure can be found at this link. Below are some pertinent points. No Implementation Rules . . . . Yet The new Implementation Rules will not be available by […]

China Releases Draft Implementation Guidelines for the Drug Administration Law

2 June 2022
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

Diagnostic Claims in China

9 January 2020
The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
Top crossarrow-right